Get the Stockscreener App
5.33
5.83%
-0.33
Kodiak Sciences Inc stock is traded at $5.33, with a volume of 262.91K.
It is down -5.83% in the last 24 hours and down -44.31% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
See More
Previous Close:
$5.66
Open:
$5.64
24h Volume:
262.91K
Relative Volume:
0.59
Market Cap:
$297.85M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-1.4176
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-16.72%
1M Performance:
-44.31%
6M Performance:
+128.76%
1Y Performance:
+13.16%
1-Day Range:
$5.27
$5.67
1-Week Range:
$5.27
$6.37
52-Week Range:
$2.185
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
5.34 | 297.85M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.85 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.70 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim - Barchart
Diabetic Retinopathy Market on Track for Major Expansion - openPR
Quarterly Dosing Breakthrough: Kodiak's New Glaucoma Treatment Targets Root Causes - StockTitan
Kodiak Sciences Inc.'s (NASDAQ:KOD) institutional investors lost 23% over the past week but have profited from longer-term gains - Simply Wall St
Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat
JPMorgan Chase & Co. Purchases 30,735 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Polaris, General Motors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Barclays PLC - Defense World
Short Interest in Kodiak Sciences Inc. (NASDAQ:KOD) Rises By 8.1% - Defense World
Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat
Jane Street Group LLC Has $90,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing - MSN
Why These 24 Stocks Are Skyrocketing - Insider Monkey
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates - MSN
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type - GlobeNewswire Inc.
Geode Capital Management LLC Acquires 12,783 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Barclays PLC - Defense World
Kodiak Sciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Crude Oil Surges 2%; Tesla Shares Plummet - Benzinga
Kodiak Sciences (NASDAQ:KOD) Shares Down 2.9%Here's What Happened - MarketBeat
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by State Street Corp - Defense World
Sanctuary Advisors LLC Reduces Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World
Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail
Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Trading Down 7.5%Time to Sell? - MarketBeat
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Trading 6.7% HigherStill a Buy? - MarketBeat
Kodiak Sciences (NASDAQ:KOD) Shares Gap UpTime to Buy? - MarketBeat
Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by Fmr LLC - Defense World
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead - Investing.com India
Critical Survey: Allogene Therapeutics (NASDAQ:ALLO) versus Kodiak Sciences (NASDAQ:KOD) - Defense World
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases - The Eastern Progress Online
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Simply Wall St
Kodiak stock rallies 32% after Jefferies upgrades to buy - MSN
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential - MSN
Nona Biosciences Partners With Kodiak Sciences For Ophthalmic Antibody Discovery - Contract Pharma
Nona Biosciences and Kodiak Sciences Inc. Partners on Next-Generation Antibody Therapies for Ophthalmic Diseases - Marketscreener.com
Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases - Seeking Alpha
Kodiak Sciences Partners with Nona Biosciences for Novel Eye Disease Antibody Development - StockTitan
Jefferies Upgrades Kodiak Sciences (KOD) - MSN
Pactiv Evergreen, RealReal, Kodiak Sciences And Other Big Stocks Moving Higher On Monday - Benzinga
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock - Yahoo Finance
Kodiak Sciences shares initiated with buy rating on positive outlook By Investing.com - Investing.com South Africa
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):